رفتن به محتوا

تداخل‌های دارویی

Aprepitant + Atogepant

شدت: متوسط

Aprepitant and Atogepant: moderate interaction.

آخرین به‌روزرسانی

ویژه کادر درمان — فقط جهت مرجع. این صفحه خلاصه‌ای کوتاه است، توصیه پزشکی نیست و جایگزین بروشور رسمی یا قضاوت بالینی نمی‌شود. پیش از تجویز یا تحویل دارو همیشه بررسی کنید.

محتوای بالینی این صفحه فقط به زبان انگلیسی موجود است.

خلاصه

Atogepant is a CYP3A4 substrate. Aprepitant inhibits CYP3A4 when given as a short course, so atogepant exposure is more likely to increase than decrease, and the legacy direction is doubtful. Higher atogepant levels may increase adverse effects such as nausea, constipation and fatigue.

معنای این تداخل به زبان ساده

Aprepitant and Atogepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Aprepitant belongs to Gastrointestinal Tract; Atogepant belongs to Central Nervous System.

سطح شواهد: Low

چرا رخ می‌دهد

Aprepitant inhibits CYP3A4, reducing atogepant metabolism, although aprepitant can also induce CYP3A4 with longer exposure.

اقدام لازم

Monitor for atogepant adverse effects during aprepitant courses. Consider dose limitation of atogepant in line with labeling for CYP3A4 inhibitors.

از داروساز چه بپرسید

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

ویژه اعضای Pro+

باز کردن کل صفحه

یک حساب بسازید و دوره آزمایشی Pro+ را شروع کنید تا توصیه‌های کامل مدیریت Aprepitant و Atogepant، یادداشت‌های تکمیلی، جزئیات شواهد و بررسی‌کننده تداخل برای کل نسخه را باز کنید.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Pro+ را ۱۴ روز رایگان در وب امتحان کنید. بدون نیاز به کارت.

پرسش‌های متداول

Can I take Aprepitant with Atogepant?

MediHelp rates the interaction as moderate. Aprepitant and Atogepant can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Atogepant is a CYP3A4 substrate. Aprepitant inhibits CYP3A4 when given as a short course, so atogepant exposure is more likely to increase than decrease, and the legacy direction is doubtful. Higher atogepant levels may increase adverse effects such as nausea, constipation and fatigue.

How serious is the interaction between Aprepitant and Atogepant?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for atogepant adverse effects during aprepitant courses. Consider dose limitation of atogepant in line with labeling for CYP3A4 inhibitors.

What other medicines interact with Aprepitant?

MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.

تک‌نگاری کامل، دوزاژ و بررسی تداخل دارویی در برنامه MediHelp

مرجع کامل را باز کنید، تداخل چند دارو را بررسی کنید و از ابزارهای دوز در برنامه MediHelp استفاده کنید.

مرور از A تا Z · تداخل‌های دارویی

دریافت برنامه ورود